

# William D Tap

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1331035/publications.pdf>

Version: 2024-02-01

125  
papers

11,088  
citations

57758

44  
h-index

33894

99  
g-index

138  
all docs

138  
docs citations

138  
times ranked

14273  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. <i>Clinical Cancer Research</i> , 2022, 28, 298-307.	7.0	12
2	Psychosocial Needs and Preferences for Care among Adolescent and Young Adult Cancer Patients (Ages 15â€“39): A Qualitative Study. <i>Cancers</i> , 2022, 14, 710.	3.7	14
3	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	1.6	13
4	CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. <i>Future Oncology</i> , 2022, , .	2.4	4
5	Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 53-66.	2.0	10
6	A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 1586-1594.	7.0	20
7	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1507-1517.	7.0	3
8	AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance. <i>Tomography</i> , 2022, 8, 341-355.	1.8	4
9	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
10	<i><sc>FGFR2</sc>::<sc>TACC2</sc></i> fusion as a novel <sc>KIT</sc>-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 412-419.	2.8	4
11	Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates. <i>Modern Pathology</i> , 2022, 35, 1055-1065.	5.5	13
12	Effect of Mild and Moderate Hepatic Impairment (Defined by Childâ€™Pugh Classification and National) Tj ETQq0 0 0 rgBT /Overlock 10 <i>Journal of Clinical Pharmacology</i> , 2022, 62, 992-1005.	2.0	3
13	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
14	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 939-947.	7.0	10
15	Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2579-2586.	7.0	4
16	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. <i>Nature Communications</i> , 2022, 13, .	12.8	63
17	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	51
18	Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1828-1836.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 480-492.	2.0	8
20	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021, 26, e863-e873.	3.7	28
21	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021, 127, 884-893.	4.1	29
22	Imaging features and clinical course of undifferentiated round cell sarcomas with CIC-DUX4 and BCOR-CCNB3 translocations. <i>Skeletal Radiology</i> , 2021, 50, 521-529.	2.0	24
23	Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. <i>Annals of Surgery</i> , 2021, 273, 128-138.	4.2	62
24	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	3.7	29
25	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 3861-3866.	7.0	22
26	Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO's Friends of Cancer Research Joint Research Statement. <i>Clinical Cancer Research</i> , 2021, 27, 2394-2399.	7.0	47
27	A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1089-1098.	2.6	19
28	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. <i>Molecular Cancer Research</i> , 2021, 19, 1146-1155.	3.4	14
29	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021, 145, 132-142.	2.8	75
30	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
31	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021, 92, 493-499.	3.3	13
32	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. <i>Cancer Medicine</i> , 2021, 10, 4221-4227.	2.8	8
33	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1422-1432.	2.5	7
34	Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2021, 7, 1343.	7.1	23
35	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	1.6	56
36	A novel image-based system for risk stratification in patients with desmoplastic small round cell tumor. <i>Journal of Pediatric Surgery</i> , 2020, 55, 376-380.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 433-444.	2.6	69
38	Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. <i>Modern Pathology</i> , 2020, 33, 591-602.	5.5	87
39	Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARCO21) trial. <i>Journal of Geriatric Oncology</i> , 2020, 11, 463-469.	1.0	7
40	Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 419-427.	7.0	60
41	The epigenomics of sarcoma. <i>Nature Reviews Cancer</i> , 2020, 20, 608-623.	28.4	121
42	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 5448-5455.	7.0	12
43	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. <i>JCO Precision Oncology</i> , 2020, 4, 1350-1360.	3.0	18
44	The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 525-534.	2.8	35
45	Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. <i>Sarcoma</i> , 2020, 2020, 1-8.	1.3	2
46	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1693-1701.	1.6	86
47	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	10.7	186
48	NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. <i>Modern Pathology</i> , 2020, 33, 1341-1349.	5.5	53
49	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	7.1	125
50	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1266.	7.4	190
51	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. <i>Clinical Cancer Research</i> , 2020, 26, 3881-3888.	7.0	59
52	Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent. <i>Cellular Physiology and Biochemistry</i> , 2020, 54, 707-718.	1.6	0
53	A phase Ib study of BCGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	2.6	32
54	Incidence and Management of Olaratumab Infusion-Related Reactions. <i>Journal of Oncology Practice</i> , 2019, 15, e925-e933.	2.5	4

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. <i>Sarcoma</i> , 2019, 2019, 1-6.	1.3	3
56	The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 6.	1.9	14
57	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , 2019, 394, 478-487.	13.7	273
58	Establishing a Mutually Respectful Environment in the Workplace: A Toolbox for Performance Excellence. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e219-e226.	3.8	9
59	Multidisciplinary care in tenosynovial giant cell tumours. <i>Lancet Oncology, The</i> , 2019, 20, 755-756.	10.7	3
60	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. <i>Oncologist</i> , 2019, 24, 857-863.	3.7	15
61	Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 191-199.	2.3	10
62	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
63	Pilot study of NKTR214 and nivolumab in patients with sarcomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11010-11010.	1.6	6
64	A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11049-11049.	1.6	12
65	Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 531-531.	1.6	0
66	Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 518-518.	1.6	0
67	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology, The</i> , 2018, 19, 416-426.	10.7	517
68	NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 791-798.	3.7	182
69	Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors. <i>Annals of Surgery</i> , 2018, 268, 296-302.	4.2	58
70	Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1384882.	0.7	5
71	Locally Aggressive Connective Tissue Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 202-209.	1.6	48
72	TOMAS: revisiting PARP inhibitor combination therapy. <i>Lancet Oncology, The</i> , 2018, 19, 1269-1270.	10.7	2

#	ARTICLE	IF	CITATIONS
73	PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. <i>Oncogene</i> , 2018, 37, 5066-5078.	5.9	38
74	Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience. <i>Urology</i> , 2018, 119, 55-61.	1.0	2
75	Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 536-563.	4.9	457
76	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	9.4	313
77	Platelet-derived growth factor receptor- $\alpha$ and - $\beta$ promote cancer stem cell phenotypes in sarcomas. <i>Oncogenesis</i> , 2018, 7, 47.	4.9	28
78	Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	1.6	8
79	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11502-11502.	1.6	16
80	A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11509-11509.	1.6	8
81	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11514-11514.	1.6	30
82	A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11516-11516.	1.6	6
83	Pilot study of NY-ESO-1 c259 T cells in advanced myxoid/round cell liposarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3005-3005.	1.6	12
84	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11590-TPS11590.	1.6	1
85	Subgroup analysis of elderly patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARCO21) trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11575-11575.	1.6	0
86	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e23570-e23570.	1.6	0
87	Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. <i>Cellular Signalling</i> , 2017, 34, 86-91.	3.6	16
88	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. <i>JAMA Oncology</i> , 2017, 3, 944.	7.1	73
89	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 319-330.e1.	0.8	96
90	BCOR upregulation in a poorly differentiated synovial sarcoma with SS18L1-SSX1 fusion: A pathologic and molecular pitfall. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 296-302.	2.8	30

#	ARTICLE	IF	CITATIONS
91	Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome. American Journal of Surgical Pathology, 2017, 41, 941-949.	3.7	278
92	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	7.0	106
93	Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?. Annals of Thoracic Surgery, 2017, 104, 1837-1845.	1.3	28
94	Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome. Annals of Surgical Oncology, 2017, 24, 3972-3980.	1.5	59
95	GeDDiS: insight into frontline therapy in soft tissue sarcoma. Lancet Oncology, The, 2017, 18, 1297-1299.	10.7	4
96	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARCO21): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1089-1103.	10.7	214
97	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. Journal of Clinical Oncology, 2017, 35, 11001-11001.	1.6	26
98	A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401).. Journal of Clinical Oncology, 2017, 35, 11007-11007.	1.6	26
99	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
100	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1<sup>c259</sup>t in HLA-A2<sup>+</sup> patients with synovial sarcoma (NCT01343043).. Journal of Clinical Oncology, 2017, 35, 3000-3000.	1.6	20
101	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. Journal of Clinical Oncology, 2017, 35, TPS11081-TPS11081.	1.6	5
102	Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).. Journal of Clinical Oncology, 2017, 35, e22518-e22518.	1.6	1
103	A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0
104	Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).. Journal of Clinical Oncology, 2017, 35, 11048-11048.	1.6	2
105	Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. Clinical Therapeutics, 2016, 38, 778-793.	2.5	79
106	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. Spine Journal, 2016, 16, 291-298.	1.3	32
107	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With<i>CDK4</i>Inhibitor Palbociclib. JAMA Oncology, 2016, 2, 937.	7.1	241
108	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet, The, 2016, 388, 488-497.	13.7	512



#	ARTICLE	IF	CITATIONS
109	Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1 $\alpha$ inhibition, and hypoxia-activated chemotherapy. <i>Oncotarget</i> , 2016, 7, 42844-42858.	1.8	18
110	MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 395-406.	4.1	83
111	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. <i>Cancer Discovery</i> , 2015, 5, 304-315.	9.4	102
112	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. <i>New England Journal of Medicine</i> , 2015, 373, 428-437.	27.0	438
113	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. <i>Human Pathology</i> , 2015, 46, 357-365.	2.0	252
114	Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome. <i>Neoplasia</i> , 2015, 17, 183-189.	5.3	33
115	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. <i>Oncologist</i> , 2015, 20, 1245-1246.	3.7	25
116	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10507-10507.	1.6	16
117	Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. <i>PLoS ONE</i> , 2015, 10, e0133610.	2.5	30
118	Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs. <i>Clinical Cancer Research</i> , 2014, 20, 3146-3158.	7.0	86
119	Phosphoproteomic Profiling Reveals IL6-Mediated Paracrine Signaling within the Ewing Sarcoma Family of Tumors. <i>Molecular Cancer Research</i> , 2014, 12, 1740-1754.	3.4	17
120	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. <i>Clinical Cancer Research</i> , 2014, 20, 4200-4209.	7.0	127
121	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. <i>Nature Genetics</i> , 2014, 46, 1227-1232.	21.4	472
122	Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1085-1091.	0.8	131
123	Phase II Study of Ganitumab, a Fully Human Anti- $\alpha$ Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 1849-1856.	1.6	198
124	Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. <i>Cancer</i> , 2012, 118, 5888-5893.	4.1	127
125	Utilization of positron emission tomography in the management of patients with sarcoma. <i>Current Opinion in Oncology</i> , 2009, 21, 345-351.	2.4	95